CARDINAL (NCT03019185) is an international, multicenter, phase 2/3 trial designed to assess the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with Alport syndrome. The CARDINAL phase 2 study was open label and enrolled 30 patients, and it is not the subject of this publication. The CARDINAL phase 3 study is an international, double-blind, randomized, placebo-controlled trial. The general design and participants' baseline characteristics from the CARDINAL phase 3 study are discussed herein.

Note: The content above has been extracted from a research article, so it may not display correctly.

Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.

We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.